GlassScriptPhysician profile
Katharine Kerchner
NPI 1700068384
$8,314.41
in general payments reported to CMS, 2019-2025
30 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 80% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $950 · 2021: $1,025 · 2022: $999 · 2023: $1,051 · 2024: $1,646 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,046.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,178.75 | 2019-2025 | |
| Abbvie INC. | $1,157.94 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,018.25 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Regeneron Healthcare Solutions, INC. | $883.25 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $480.42 | 2019-2024 | Taltz, Olumiant |
| Janssen Biotech, INC. | $448.84 | 2019-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $447.63 | 2022-2025 | Sotyktu |
| Amgen INC. | $377.88 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $338.55 | 2019-2025 | |
| Ucb, INC. | $254.81 | 2019-2025 | Bimzelx |
| Genentech USA, INC. | $237.75 | 2019-2022 | |
| Smith+Nephew, INC. | $220.50 | 2019-2025 | Grafix Pl, Stravix Pl, Oasis |
| Mayne Pharma Commercial LLC | $209.68 | 2019-2025 | |
| Pfizer INC. | $157.25 | 2019-2024 | |
| Organogenesis INC. | $134.02 | 2019-2024 | Affinity |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.45 | 2022-2025 | Spevigo |
| Osiris Therapeutics INC. | $94.42 | 2019 | |
| Incyte Corporation | $91.83 | 2021-2025 | Opzelura |
| Biofrontera INC. | $78.83 | 2022-2025 | Ameluz, Bf-Rhodoled, Xepi |
| Vyne Pharmaceuticals INC. | $64.37 | 2020-2021 | |
| Almirall LLC | $63.62 | 2022-2024 | Seysara |
| Revance Therapeutics, INC. | $59.39 | 2025 | Daxxify |
| Celgene Corporation | $55.68 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.35 | 2019 | |
| Sensus Healthcare, INC. | $28.31 | 2021 | |
| Leo Pharma INC. | $26.32 | 2025 | Adbry |
| Merck Sharp & Dohme LLC | $24.10 | 2022 | |
| Dermavant Sciences, INC. | $22.11 | 2024 | Vtama |
| Mallinckrodt Hospital Products INC. | $19.69 | 2025 | Acthar |
| Helsinn Therapeutics (U.S.), INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katharine Kerchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.